NCT06846671: An ongoing trial by BeOne Medicines
This trial is ongoing. It must report results 3 years, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06846671 |
|---|---|
| Title | A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 10, 2025 |
| Completion date | May 15, 2028 |
| Required reporting date | May 15, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |